RPHM Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences.

Citi BioPharma ConferenceDate: Wednesday, September 6 – Thursday, September 7, 2023Location: Four Seasons, Boston, MA

Baird Global Healthcare ConferenceDate: Tuesday, September 12 – Wednesday, September 13, 2023Location: InterContinental New York Barclay, New York, NY

Leerink Partners Biopharma SummitDate: Wednesday, September 20 – Friday, September 22, 2023 Location: Rosewood Miramar Beach, Montecito, CA

Cantor Global Healthcare ConferenceDate: Tuesday, September 26 – Thursday, September 28, 2023Location: InterContinental New York Barclay, New York, NY

Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.

About Reneo PharmaceuticalsReneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler Investor Relations Reneo Pharmaceuticals, Inc. dspangler@reneopharma.com

Matthew Purcell, Pharm.D.Media Inquiries Russo Partners, LLC matthew.purcell@russopartnersllc.com